{"id":440768,"date":"2021-02-22T09:03:27","date_gmt":"2021-02-22T14:03:27","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=440768"},"modified":"2021-02-22T09:03:27","modified_gmt":"2021-02-22T14:03:27","slug":"cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\/","title":{"rendered":"Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families"},"content":{"rendered":"

<\/p>\n

Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families<\/b><\/p>\n

– The evolution of the Company\u2019s brand identity aligns with Cyclo Therapeutics\u2019 science-based, patient-focus approach to drug development<\/i><\/p>\n

– Company developing cyclodextrin-based products for the treatment of diseases with significant unmet needs, including Niemann-Pick Disease Type C (NPC) and Alzheimer\u2019s Disease (AD)<\/i><\/p>\n

GAINESVILLE, Fla.–(BUSINESS WIRE<\/a>)–Cyclo Therapeutics, Inc.<\/a> (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer\u2019s Disease, today unveiled its new corporate identity, which is intended to emphasize the Company\u2019s commitment to improving quality of life, providing hope for patients and families through innovative life-changing medicine, and bringing awareness that we are all in this together.\n<\/p>\n

\n\u201cThis coming Sunday, February 28th<\/sup>, is Rare Disease Day, an event meant to bring attention and hope to patients and families suffering from devastating and rare diseases, and who are left without treatment options,\u201d commented N. Scott Fine, CEO of Cyclo Therapeutics. \u201cIn recognition of Rare Disease Day, we reaffirm our commitment to patients and families. Our re-branding reflects an identity in line with our mission and vision to bring hope to patients and families in indications where there remains significant unmet medical need.\u201d\n<\/p>\n

Mission: <\/b><\/p>\n

\nDedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease.\n<\/p>\n

Vision: <\/b><\/p>\n

\nProviding hope through patient-focused drug development to improve quality of life.\n<\/p>\n

\nThe Company\u2019s lead product in development, Trappsol\u00ae<\/sup> Cyclo\u2122, is a proprietary formulation of hydroxypropyl beta cyclodextrin used intravenously (IV). Trappsol\u00ae<\/sup> Cyclo\u2122 is currently in development for the treatment of NPC1, a rare genetic disorder causing cholesterol accumulation in lysosomes of cells, organ dysfunction and premature death. Functioning like the NPC1 protein, Trappsol\u00ae<\/sup> Cyclo\u2122 has been shown to transport cholesterol out of cells, normalizing cholesterol metabolism. Following review of the Company\u2019s Phase 1 and Phase 1\/2 data, coupled with preclinical and compassionate use data, regulatory authorities acknowledged that IV hydroxypropyl beta cyclodextrin has the potential to treat systemic and neurologic manifestations of NPC and has the capacity when given intravenously to be a preventative treatment. The Company received FDA acknowledgment that the pivotal Phase 3 study may begin, and enrollment is targeted to commence in Q2 2021.\n<\/p>\n

\nAdditionally, based on encouraging data from an Expanded Access program for late-onset Alzheimer\u2019s Disease, the Company is planning to initiate an early phase clinical trial evaluating the use of Trappsol\u00ae<\/sup> Cyclo\u2122 intravenously for the treatment of Alzheimer\u2019s Disease.\n<\/p>\n

\nFor more information about the Cyclo Therapeutics and its pipeline of products in development, please visit: www.cyclotherapeutics.com<\/a><\/p>\n

About Cyclo Therapeutics<\/b><\/p>\n

\nCyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The company\u2019s Trappsol\u00ae<\/sup> Cyclo\u2122, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547<\/a>, NCT02912793<\/a> and NCT02912793<\/a>). The company is planning an early phase clinical trial using Trappsol\u00ae<\/sup> Cyclo\u2122 intravenously in Alzheimer\u2019s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer\u2019s Disease (NCT03624842<\/a>). Additional indications for the active ingredient in Trappsol\u00ae<\/sup> Cyclo\u2122 are in development. For additional information, visit the company\u2019s website: www.cyclotherapeutics.com<\/a>.\n<\/p>\n

Safe Harbor Statement<\/b><\/p>\n

\nThis press release contains \u201cforward-looking statements\u201d about the company\u2019s current expectations about future results, performance, prospects and opportunities, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering. Statements that are not historical facts, such as \u201canticipates,\u201d \u201cbelieves\u201d and \u201cexpects\u201d or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company\u2019s future performance include the company\u2019s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company\u2019s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company\u2019s filings with the Securities and Exchange Commission, including, but not limited to, the company\u2019s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210222005186\/en\/<\/a><\/span><\/p>\n

Investors:
\n<\/b>
JTC Team, LLC
\n
Jenene Thomas
\n
(833) 475-8247
\n
CYTH@jtcir.com<\/a><\/p>\n

KEYWORDS:<\/b> Florida United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Mental Health FDA Health Clinical Trials Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families – The evolution of the Company\u2019s brand identity aligns with Cyclo Therapeutics\u2019 science-based, patient-focus approach to drug development – Company developing cyclodextrin-based products for the treatment of diseases with significant unmet needs, including Niemann-Pick Disease Type C (NPC) and Alzheimer\u2019s Disease (AD) GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer\u2019s Disease, today unveiled its new corporate identity, which is intended to emphasize the Company\u2019s commitment to improving quality of life, providing hope for patients and families through … <\/p>\n

Continue reading “Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-440768","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families – The evolution of the Company\u2019s brand identity aligns with Cyclo Therapeutics\u2019 science-based, patient-focus approach to drug development – Company developing cyclodextrin-based products for the treatment of diseases with significant unmet needs, including Niemann-Pick Disease Type C (NPC) and Alzheimer\u2019s Disease (AD) GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer\u2019s Disease, today unveiled its new corporate identity, which is intended to emphasize the Company\u2019s commitment to improving quality of life, providing hope for patients and families through … Continue reading "Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-22T14:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210222005186r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families\",\"datePublished\":\"2021-02-22T14:03:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\\\/\"},\"wordCount\":861,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210222005186r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\\\/\",\"name\":\"Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210222005186r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-02-22T14:03:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210222005186r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210222005186r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\/","og_locale":"en_US","og_type":"article","og_title":"Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families - Market Newsdesk","og_description":"Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families – The evolution of the Company\u2019s brand identity aligns with Cyclo Therapeutics\u2019 science-based, patient-focus approach to drug development – Company developing cyclodextrin-based products for the treatment of diseases with significant unmet needs, including Niemann-Pick Disease Type C (NPC) and Alzheimer\u2019s Disease (AD) GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (\u201cCyclo Therapeutics\u201d or the \u201cCompany\u201d), a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer\u2019s Disease, today unveiled its new corporate identity, which is intended to emphasize the Company\u2019s commitment to improving quality of life, providing hope for patients and families through … Continue reading \"Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-22T14:03:27+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210222005186r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families","datePublished":"2021-02-22T14:03:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\/"},"wordCount":861,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210222005186r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\/","name":"Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210222005186r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-02-22T14:03:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210222005186r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210222005186r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cyclo-therapeutics-unveils-new-corporate-identity-and-reaffirms-commitment-to-improving-quality-of-life-and-providing-hope-for-patients-and-families\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/440768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=440768"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/440768\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=440768"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=440768"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=440768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}